Novartis

Warning signs were always there for Novartis’s Avexis deal
EP Vantage
Fri, 08/16/19 - 10:01 am
Novartis
AveXis
AveXis scientific founder is out as Novartis names a new CSO in wake of an ethics scandal
Endpoints
Wed, 08/14/19 - 11:15 am
Novartis
AveXis
Zolgensma
FDA
Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Pharmaceutical Business Review
Wed, 08/14/19 - 11:13 am
Novartis
Sandoz
biosimilars
Amgen
Enbrel
patents
Erelzi
Novartis names Bulto as new head of U.S. drugs business
Yahoo/Reuters
Wed, 08/14/19 - 10:15 am
Novartis
Victor Bulto
Novartis inspection puts into question who knew what—and when—about Zolgensma data manipulation
Fierce Pharma
Tue, 08/13/19 - 11:20 pm
Novartis
FDA
Zolgensma
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
Tue, 08/13/19 - 11:43 am
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Questions pile up for Novartis as senators call on FDA to take action
Endpoints
Tue, 08/13/19 - 11:41 am
Novartis
FDA
Senate
Zolgensma
Novartis sells phase 3 rare disease drug to Pharming
Fierce Biotech
Tue, 08/13/19 - 10:06 am
Novartis
Pharming
leniolisib
Questions Pile up for Novartis as Senators Call on FDA to Take Action
RAPS.org
Mon, 08/12/19 - 05:28 pm
FDA
Novartis
5 Reasons Novartis Shareholders Aren't Shaken
Yahoo/Motley Fool
Mon, 08/12/19 - 10:32 am
Novartis
Zolgensma
FDA
shareholders
Entresto
Novartis resolute that it acted in good faith on Zolgensma
BioCentury
Wed, 08/7/19 - 11:54 pm
Novartis
data
Zolgensma
FDA
Novartis used manipulated data in winning Zolgensma approval, FDA says
Biopharma Dive
Wed, 08/7/19 - 10:57 am
Novartis
FDA
Zolgensma
data
spinal muscular atrophy
gene therapy
AveXis
Novartis' Kisqali sharpens survival edge with second ph3 win
Fierce Pharma
Thu, 08/1/19 - 12:00 am
Novartis
Kisqali
breast cancer
clinical trials
Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy
Endpoints
Wed, 07/31/19 - 10:24 am
Novartis
Vas Narasimhan
M&A
Pharma CEOs
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Yahoo/Reuters
Tue, 07/30/19 - 07:51 am
lymphoma
Gilead Siences
Novartis
cell therapies
Kymriah
Yescarta
Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU
RAPS.org
Mon, 07/29/19 - 11:19 pm
Novartis
Zolgensma
CHMP
Europe
SMA
Novartis heart drug fails trial, curbing growth prospects
Yahoo/Reuters
Mon, 07/29/19 - 09:26 am
Novartis
heart failure
Entresto
clinical trials
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Pharmaceutical Business Review
Tue, 07/23/19 - 10:03 am
Novartis
Sandoz
biosimilars
clinical trials
denosumab
osteoporosis
Prolia
Xgeva
24 insurers have policies on coverage of world's most expensive drug
Beckers Hospital Review
Mon, 07/22/19 - 08:13 pm
Novartis
payers
insurance
Medicaid
SMA
drug pricing
Zolgensma
Novartis multiple sclerosis product Gilenya approved in China
Pharmaceutical Business Review
Mon, 07/22/19 - 09:45 am
China
Novartis
multiple sclerosis
Gilenya

Pages